Overview

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, multicenter, open-label, active-controlled, efficacy, and safety study in adult hypogonadal men. The study duration is 12 months (365 days), including a 90-day, open-label efficacy period and a 9-month (275-day) safety evaluation period.
Phase:
Phase 3
Details
Lead Sponsor:
Marius Pharmaceuticals
Collaborators:
INC Research
Syneos Health
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate